Double-blind controlled trial of purified brain gangliosides in amyotrophic lateral sclerosis and experience with peripheral neuropathies.

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

A double-blind control trial of 40 mg purified brain gangliosides in 40 patients with ALS for six months showed no significant improvement with the drug. An open trial of the same dose of ganglioside for the same period showed measurable improvement in six out of ten patients with a variety of peripheral motor and sensory neuronal degenerations. These studies indicate the need for continuing clinical investigation of the therapeutic usefulness of the purified brain gangliosides.

Original languageEnglish
Pages (from-to)565-573
Number of pages9
JournalAdvances in Experimental Medicine and Biology
Volume174
StatePublished - Jan 1 1984
Externally publishedYes

Fingerprint

Gangliosides
Amyotrophic Lateral Sclerosis
Peripheral Nervous System Diseases
Brain
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

@article{7b477404a4d24aec9a9aa75d430752b1,
title = "Double-blind controlled trial of purified brain gangliosides in amyotrophic lateral sclerosis and experience with peripheral neuropathies.",
abstract = "A double-blind control trial of 40 mg purified brain gangliosides in 40 patients with ALS for six months showed no significant improvement with the drug. An open trial of the same dose of ganglioside for the same period showed measurable improvement in six out of ten patients with a variety of peripheral motor and sensory neuronal degenerations. These studies indicate the need for continuing clinical investigation of the therapeutic usefulness of the purified brain gangliosides.",
author = "Bradley, {Walter G}",
year = "1984",
month = "1",
day = "1",
language = "English",
volume = "174",
pages = "565--573",
journal = "Advances in Experimental Medicine and Biology",
issn = "0065-2598",
publisher = "Springer New York",

}

TY - JOUR

T1 - Double-blind controlled trial of purified brain gangliosides in amyotrophic lateral sclerosis and experience with peripheral neuropathies.

AU - Bradley, Walter G

PY - 1984/1/1

Y1 - 1984/1/1

N2 - A double-blind control trial of 40 mg purified brain gangliosides in 40 patients with ALS for six months showed no significant improvement with the drug. An open trial of the same dose of ganglioside for the same period showed measurable improvement in six out of ten patients with a variety of peripheral motor and sensory neuronal degenerations. These studies indicate the need for continuing clinical investigation of the therapeutic usefulness of the purified brain gangliosides.

AB - A double-blind control trial of 40 mg purified brain gangliosides in 40 patients with ALS for six months showed no significant improvement with the drug. An open trial of the same dose of ganglioside for the same period showed measurable improvement in six out of ten patients with a variety of peripheral motor and sensory neuronal degenerations. These studies indicate the need for continuing clinical investigation of the therapeutic usefulness of the purified brain gangliosides.

UR - http://www.scopus.com/inward/record.url?scp=0021298875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021298875&partnerID=8YFLogxK

M3 - Article

C2 - 6331136

AN - SCOPUS:0021298875

VL - 174

SP - 565

EP - 573

JO - Advances in Experimental Medicine and Biology

JF - Advances in Experimental Medicine and Biology

SN - 0065-2598

ER -